ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Lijuan Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0429-036X; OpenAlex author ID A5067160599. Sources: OpenAlex.

Their work

Papers: 3 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 5

Papers, trials and grants by year

2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 3

Machine learning-optimized metabolic biomarker panel for precision screening of early-stage pancreatic cancer in new-onset diabetes. Last author DOI 10.3389/fendo.2025.1684608 ↗
GATA4 Regulates Inflammation-Driven Pancreatic Ductal Adenocarcinoma Progression. Last author DOI 10.3389/fcell.2021.640391 ↗
Overexpression of ERCC3 is associated with poor prognosis in patients with pancreatic cancer. Co-author DOI 10.7150/jca.54576 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Weiliang Jiang · 2 shared papers, 2021–2025 · strength 0.44
- Paper Machine learning-optimized metabolic biomarker panel for precision screening of early-stage pancreatic cancer in new-on… DOI 10.3389/fendo.2025.1684608 ↗
- Paper GATA4 Regulates Inflammation-Driven Pancreatic Ductal Adenocarcinoma Progression. DOI 10.3389/fcell.2021.640391 ↗
Zhiyuan Cheng · 1 shared paper, 2025 · strength 0.27
- Paper Machine learning-optimized metabolic biomarker panel for precision screening of early-stage pancreatic cancer in new-on… DOI 10.3389/fendo.2025.1684608 ↗
Congying Chen · 1 shared paper, 2021 · strength 0.17
- Paper GATA4 Regulates Inflammation-Driven Pancreatic Ductal Adenocarcinoma Progression. DOI 10.3389/fcell.2021.640391 ↗
Shujie Wang · 1 shared paper, 2021 · strength 0.11
- Paper Overexpression of ERCC3 is associated with poor prognosis in patients with pancreatic cancer. DOI 10.7150/jca.54576 ↗
Zhe Yang · 1 shared paper, 2021 · strength 0.11
- Paper Overexpression of ERCC3 is associated with poor prognosis in patients with pancreatic cancer. DOI 10.7150/jca.54576 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.